Celltrion Strikes $278m Deal With Takeda
Korean Firm Expands In APAC, Small Molecules Via Takeda Asset Buy
Executive Summary
Celltrion has bought a portfolio of selected products in the Asia-Pacific region from Takeda, marking a foray into small-molecule drugs.